Quantcast
Last updated on April 19, 2014 at 7:50 EDT

Latest Biosimilar Stories

2013-11-22 04:21:00

DUBLIN, Nov. 22, 2013 /PRNewswire/ -- The Alliance for Safe Biologic Medicines (ASBM) today released the results of a new survey on European physicians' views on biosimilar naming. ASBM Executive Director Michael Reilly presented the findings at the Drug Information Association (DIA) Biosimilars Workshop in Dublin, Ireland. The key findings showed that nonproprietary names matter to patient safety. The survey examined responses from more than 470 prescribers located in the United Kingdom,...

2013-11-21 16:26:49

DUBLIN, November 21, 2013 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/qms499/bioseparation) has announced the addition of the "Bioseparation Systems for Global Biopharmaceutical Markets" [http://www.researchandmarkets.com/research/qms499/bioseparation ] report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) This new report, "Global Markets for Bioseparations for Biopharmaceutical...

2013-11-20 12:24:46

IRVING, Texas, Nov. 20, 2013 /PRNewswire/ -- Health systems professionals should prepare now for the introduction of biosimilars, a new category of pharmaceuticals intended to offer lower cost alternatives for some of the most expensive medications purchased by health care organizations. This insight comes from newly published research co-authored by Novation, the leading health care supply chain expertise, analytics and contracting company. The primer, "Biosimilars: Implications...

2013-11-18 12:29:12

DALLAS, November 18, 2013 /PRNewswire/ -- The "Biosimilars Market Product [Recombinant Non-Glycosylated Proteins (Insulin, Filgrastim, Somatropin), Glycosylated (Monoclonal Antibodies, Erythropoietin), Peptides (Glucagon, Calcitonin)] & Application (Oncology, Blood Disorders) - Global Forecast to 2018", provides a detailed overview of the major drivers, restraints, challenges, opportunities, current market trends, and strategies impacting the global Biosimilars Market...

2013-11-14 08:34:10

DUBLIN, Nov. 14, 2013 /PRNewswire/ -- Actavis plc (NYSE: ACT) today confirmed that it has filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Testosterone Topical Solution, 30mg/1.5mL. Actavis' ANDA product is a generic version of Eli Lilly and Company's Axiron(®), which is an androgen indicated for replacement therapy in males for conditions associated with a deficiency or absence of endogenous...

2013-11-11 23:00:10

Kantar Health Presentation at EphMRA Asia Conference to Deliver New Insights New York, NY (PRWEB) November 12, 2013 Kantar Health, a leading global healthcare consulting firm, will release new details on biosimilar opportunities and challenges for pharmaceutical manufacturers in Asia at the EphMRA 2013 Asia Conference on November 14 in Singapore. Questa Lin, General Manager, Taiwan, and Simon Li, General Manager, China, will present. In their presentation, “Uncover Biosimilars...

2013-11-07 23:32:07

Cato Research clinical research physician and managing director for Cato Research’s Washington office, Jack Snyder, M.D., Ph.D., R.A.C., D.A.B.T., C.P.I., and Cato Research regulatory expert Elinore M. Mercer, Ph.D., R.A.C., will present in Rockville, Maryland, at the Korea-Maryland, United States of America Bio Expo, Drug Development Process and Regulatory Approaches. Durham, NC (PRWEB) November 07, 2013 Cato Research clinical research physician and managing director for Cato...

2013-10-31 08:33:35

However, Changes in Treatment Practices Via Improved Originator Biologics Threaten Biosimilar Uptake, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 31, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that surveyed U.S. and European oncologists will cautiously adopt biosimilar monoclonal antibodies initially; only a minority of oncologists say they will...

2013-10-30 16:26:23

- Novartis files Citizen Petition with FDA, urging uniform approach to use of international nonproprietary names (INN) for all biologic medicines BASEL, Switzerland, Oct. 30, 2013 /PRNewswire/ -- Novartis announced today it has filed a Citizen Petition with the U.S. Food and Drug Administration (FDA), urging the Agency to require that a biosimilar share the same INN as the reference product. Novartis argues that changing the well-established convention that the INN describes the active...

2013-10-29 23:28:03

Xtalks presents an exciting live webinar on Wednesday, November 6, 2013 at 11:00am EDT (16:00h GMT) with keynote speaker Dr. Sinnathamby Gomathinayagam, Senior Scientist at Covance’s Biomarker Center of Excellence. Toronto, Canada (PRWEB) October 29, 2013 Biologics have transformed the way several diseases have been traditionally treated and managed over the past several years. Therapeutic antibodies are a class of biologics that has been exceptionally effective in the treatment of life...